We are delighted to report that Xceleron has been acquired by Pharmaron, a fully integrated CRO offering R&D services, headquartered in Beijing, with operations in China, the USA and the UK. Our press release can be downloaded here. The Xceleron team will be retained and expanded by Pharmaron and we expect client interactions to continue as usual.
We are thrilled that Pharmaron recognize the value of AMS as a contemporary analytical technology in the same way that we do. Let us know if you’d like to hear more.
Pharmaron Acquires Majority Stake in SNBL CPC
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.